EICHORCondition: Glioblastoma · Sponsor: Haukeland University Hospital
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent grade-4 with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
This description comes directly from the study's public registry record.
Dorota Goplen, MD, PhD · +47 55974019 · dgop@helse-bergen.no
Martha E Chekenya, PhD, Dr. Philos · +47 55586380 · martha.enger@uib.no
Always discuss trial participation with your own doctor first.
| Haukeland University Hospital | Bergen, Norway | Recruiting |
| Oslo University Hospital | Oslo, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03643549